Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen The izokibep clinical rollercoaster took off just months after Acelyrin went public in May 2023.

BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.

Amgen (NASDAQ:AMGN) traded lower on Wednesday as Wells Fargo downgraded the Dow component to Equal Weight from Overweight, arguing that the stock already reflects a potential trial success for the ...

The company has reshuffled its executive team, cut back spending and trimmed its drug pipeline this year, changes aimed at ...

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as ...

As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...

Amgen shares fell 5% Wednesday after the drug developer lowered its full-year earnings guidance. Second-quarter revenue jumped 20% year-over-year to $8.4 billion, slightly above expectations ...

The FTC said in its complaint that Amgen would be able to leverage its ... President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected ...

Betfair preview for the Amgen Irish Open at Royal County Down with tips, latest odds and starting prices along with form stats by Andy Swales ...

Sept 4 (Reuters) - Amgen (AMGN.O), opens new tab will test ... though U.S. stock futures did rally from an early dip and bond yields came off their lows. European Marketscategory China's consumer ...

Speaking on a conference call Tuesday, executives at Amgen again fielded a long slate ... Precigen Therapeutics on Wednesday said it would lay off 20% of its workforce as part of a “strategic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...